Cyclo Therapeutics reports Q2 net loss approximately $6M

Reports Net loss for the quarter ended June 30, was approximately $6M. Research and development expenses increased 10% to $3.5 million for the quarter ended June 30, 2024, from $3.2M for the quarter ended June 30, 2023. The increase in research and development expense resulted from the increase of spending related to the completion of enrollment of 94 patients in the NPC program. .”The second quarter represents a transformative time for the Company with the achievement of a landmark milestone — the completion of enrollment in our pivotal TransportNPC trial. I am extremely pleased with the progress our entire team has made with this important program. Equipped with the positive support, feedback and alignment from our recent health authority interactions with both the FDA and EMA coupled with the completion of enrollment, we are highly focused on the interim data readout expected in Q1 2025. What this means is that we believe we will be generating the data required to provide a much-needed treatment option for the treatment of NPC1,” commented N. Scott Fine, CEO of Cyclo Therapeutics. The Company ended the quarter with approximately $1.1M of cash.